Literature DB >> 29997212

Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.

Ross W Walton1, Michael C Brown2, Matthew T Sacco1, Matthias Gromeier3,2.   

Abstract

We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 (Sabin) poliovirus vaccine carrying a heterologous internal ribosomal entry site (IRES) of human rhinovirus type 2 (HRV2). Intratumoral infusion of PVSRIPO is showing promise in the therapy of recurrent WHO grade IV malignant glioma (glioblastoma), a notoriously treatment-refractory cancer with dismal prognosis. PVSRIPO exhibits profound cytotoxicity in infected neoplastic cells expressing the poliovirus receptor CD155. In addition, it elicits intriguing persistent translation and replication, giving rise to sustained type I interferon (IFN)-dominant proinflammatory stimulation of antigen-presenting cells. A key determinant of the inflammatory footprint generated by neoplastic cell infection and its role in shaping the adaptive response after PVSRIPO tumor infection is the virus's inherent relationship to the host's innate antiviral response. In this report, we define subversion of innate host immunity by PVSRIPO, enabling productive viral translation and cytopathogenicity with extremely low multiplicities of infection in the presence of an active innate antiviral IFN response.IMPORTANCE Engaging innate antiviral responses is considered key for instigating tumor-antigen-specific antitumor immunity with cancer immunotherapy approaches. However, they are a double-edged sword for attempts to enlist viruses in such approaches. In addition to their role in the transition from innate to adaptive immunity, innate antiviral IFN responses may intercept the viral life cycle in cancerous cells, prevent viral cytopathogenicity, and restrict viral spread. This has been shown to reduce overall antitumor efficacy of several proposed oncolytic virus prototypes, presumably by limiting direct cell killing and the ensuing inflammatory profile within the infected tumor. In this report, we outline how an unusual recalcitrance of polioviruses toward innate antiviral responses permits viral cytotoxicity and propagation in neoplastic cells, combined with engaging active innate antiviral IFN responses.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  MDA5; cancer; encephalomyocarditis virus; immunotherapy; innate immunity; oncolytic virus; poliovirus; type I interferon

Mesh:

Substances:

Year:  2018        PMID: 29997212      PMCID: PMC6146809          DOI: 10.1128/JVI.00879-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 2.  Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.

Authors:  Javier G Casado; Graham Pawelec; Sara Morgado; Beatriz Sanchez-Correa; Elena Delgado; Inmaculada Gayoso; Esther Duran; Rafael Solana; Raquel Tarazona
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

3.  Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry.

Authors:  Mike Strauss; David J Filman; David M Belnap; Naiqian Cheng; Roane T Noel; James M Hogle
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

4.  The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.

Authors:  Melinda K Merrill; Matthias Gromeier
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Enterovirus 2Apro targets MDA5 and MAVS in infected cells.

Authors:  Qian Feng; Martijn A Langereis; Marie Lork; Mai Nguyen; Stanleyson V Hato; Kjerstin Lanke; Luni Emdad; Praveen Bhoopathi; Paul B Fisher; Richard E Lloyd; Frank J M van Kuppeveld
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

Review 6.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

7.  MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1.

Authors:  Michael C Brown; Matthias Gromeier
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

8.  Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex.

Authors:  D Etchison; S C Milburn; I Edery; N Sonenberg; J W Hershey
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

9.  STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Authors:  Joshua D Jackson; James M Markert; Li Li; Steven L Carroll; Kevin A Cassady
Journal:  Mol Cancer Res       Date:  2016-02-16       Impact factor: 5.852

Review 10.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

View more
  14 in total

Review 1.  Developing Picornaviruses for Cancer Therapy.

Authors:  Cormac McCarthy; Nadishka Jayawardena; Laura N Burga; Mihnea Bostina
Journal:  Cancers (Basel)       Date:  2019-05-16       Impact factor: 6.639

Review 2.  Clinically Explored Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma in Adults.

Authors:  Amanda V Immidisetti; Chibueze D Nwagwu; David C Adamson; Nitesh V Patel; Anne-Marie Carbonell
Journal:  Biomedicines       Date:  2021-02-01

3.  IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma.

Authors:  Miika Martikainen; Mohanraj Ramachandran; Roberta Lugano; Jing Ma; Minttu-Maria Martikainen; Anna Dimberg; Di Yu; Andres Merits; Magnus Essand
Journal:  Mol Ther Oncolytics       Date:  2021-03-17       Impact factor: 7.200

4.  Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.

Authors:  Georgia M Beasley; Smita K Nair; Norma E Farrow; Karenia Landa; Maria Angelica Selim; Carol Ann Wiggs; Sin-Ho Jung; Darell D Bigner; Andrea True Kelly; Matthias Gromeier; April Ks Salama
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

5.  Enterovirus 2Apro Cleavage of the YTHDF m6A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling.

Authors:  Jonathan P Kastan; Martine W Tremblay; Michael C Brown; Joseph D Trimarco; Elena Y Dobrikova; Mikhail I Dobrikov; Matthias Gromeier
Journal:  mBio       Date:  2021-04-13       Impact factor: 7.867

Review 6.  Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.

Authors:  Sarah E Blitz; Ari D Kappel; Florian A Gessler; Neil V Klinger; Omar Arnaout; Yi Lu; Pier Paolo Peruzzi; Timothy R Smith; Ennio A Chiocca; Gregory K Friedman; Joshua D Bernstock
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

Review 7.  Effects of oncolytic viruses and viral vectors on immunity in glioblastoma.

Authors:  Penghao Liu; Yaning Wang; Wenbin Ma; Yu Wang; Yuekun Wang; Ziren Kong; Wanqi Chen; Jiatong Li; Wenlin Chen; Yuanren Tong
Journal:  Gene Ther       Date:  2020-11-15       Impact factor: 5.250

Review 8.  Current status of intralesional agents in treatment of malignant melanoma.

Authors:  Misam Zawit; Umang Swami; Hassan Awada; Joyce Arnouk; Mohammed Milhem; Yousef Zakharia
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Authors:  Yogesh R Suryawanshi; Autumn J Schulze
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048

Review 10.  Pattern recognition receptors in health and diseases.

Authors:  Danyang Li; Minghua Wu
Journal:  Signal Transduct Target Ther       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.